Trial Profile
Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM-KyCyDex
- 05 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 05 Sep 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 01 Apr 2021 Status changed from recruiting to active, no longer recruiting.